First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide

[1] Stupp R(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-996

[2] Mason WP(2017)Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial JAMA 318 2306-2316

[3] van den Bent MJ(2014)Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma N Engl J Med. 370 709-722

[4] Stupp R(2014)A randomized trial of bevacizumab for newly diagnosed glioblastoma N Engl J Med 370 699-708

[5] Taillibert S(2016)Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio Neuro Oncol 18 1313-1318

[6] Kanner A(2013)Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis Cancer 119 3489-3495

[7] Chinot OL(2014)Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era Cancer Med 3 660-666

[8] Wick W(2017)Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: a population-based study Oncotarget 8 44015-44031

[9] Mason W(2015)Bevacizumab for glioblastoma Ther Clin Risk Manage 11 1759-1765

[10] Gilbert MR(2018)The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in the patients with glioblastoma and anaplastic astrocytoma J Neurosurg Sci 6 105-110

[1] Stupp R(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-996

[2] Mason WP(2017)Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial JAMA 318 2306-2316

[3] van den Bent MJ(2014)Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma N Engl J Med. 370 709-722

[4] Stupp R(2014)A randomized trial of bevacizumab for newly diagnosed glioblastoma N Engl J Med 370 699-708

[5] Taillibert S(2016)Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio Neuro Oncol 18 1313-1318

[6] Kanner A(2013)Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis Cancer 119 3489-3495

[7] Chinot OL(2014)Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era Cancer Med 3 660-666

[8] Wick W(2017)Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: a population-based study Oncotarget 8 44015-44031

[9] Mason W(2015)Bevacizumab for glioblastoma Ther Clin Risk Manage 11 1759-1765

[10] Gilbert MR(2018)The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in the patients with glioblastoma and anaplastic astrocytoma J Neurosurg Sci 6 105-110